{"transactions":[{"id":748088,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-05T11:54:18.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":12500,"derivative":{"exercise_price":30.91,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-258422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526258422/ownership.xml","form_type":"4"}},{"id":1119779,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-06T12:03:39.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":16000,"derivative":{"exercise_price":11.86,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-082701","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025082701/ownership.xml","form_type":"4"}},{"id":1260090,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (Right to Buy)","published_at":"2025-02-20T00:29:06.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 14, 2029."}],"balance_after":180000,"derivative":{"exercise_price":0.76,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001739410-25-000013","document":"wk-form4_1740011340.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000013/wk-form4_1740011340.xml","form_type":"4"}},{"id":1407722,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T21:17:43.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":15963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":15963,"derivative":{"exercise_price":16,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":15963},"source":{"system":"sec-edgar","filing":"0000950170-24-106476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024106476/ownership.xml","form_type":"4"}},{"id":1638340,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (Right to Buy)","published_at":"2024-02-16T23:18:50.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 15, 2028."}],"balance_after":120000,"derivative":{"exercise_price":1.86,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001739410-24-000017","document":"wk-form4_1708125519.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000017/wk-form4_1708125519.xml","form_type":"4"}},{"id":1773130,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2137,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":2137},"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1773129,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":441,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":441},"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1773128,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5492,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":5492},"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1773127,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6038,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":6038},"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1773126,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":1322},"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1773125,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-09-26T16:30:22.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000089924323019536/doc4.xml","form_type":"4"}},{"id":1860192,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-06-09T16:38:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":2137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":2137,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":2137},"source":{"system":"sec-edgar","filing":"0001209191-23-035909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123035909/doc4.xml","form_type":"4"}},{"id":1860191,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2023-06-09T16:38:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":441,"price":73.68,"value":32492.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $32,494."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":441,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":441},"source":{"system":"sec-edgar","filing":"0001209191-23-035909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123035909/doc4.xml","form_type":"4"}},{"id":1860190,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-06-09T16:38:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":1682,"price":93.61,"value":157452.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date."}],"balance_after":10907,"source":{"system":"sec-edgar","filing":"0001209191-23-035909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123035909/doc4.xml","form_type":"4"}},{"id":1860189,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2023-06-09T16:38:13.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":347,"price":93.61,"value":32482.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $32,483."}],"balance_after":9225,"source":{"system":"sec-edgar","filing":"0001209191-23-035909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919123035909/doc4.xml","form_type":"4"}},{"id":2030651,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (Right to Buy)","published_at":"2023-02-06T22:40:53.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":119000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 6, 2027."}],"balance_after":119000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":119000},"source":{"system":"sec-edgar","filing":"0000899243-23-004077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323004077/doc4.xml","form_type":"4"}},{"id":2208483,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":5492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in four equal installments on September 8, 2022, December 8, 2022, March 8, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":5492,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":5492},"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2208482,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":6038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest in three equal yearly installments, subject to continued service through each vesting date."}],"balance_after":6038,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":6038},"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2208481,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right-to-buy)","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":1322,"price":22.36,"value":29559.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $29,557.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in four equal installments on September 8, 2022, December 8, 2022, March 8, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":1322,"derivative":{"exercise_price":32.36,"expiration_date":"2032-07-11","underlying":"Class A common stock","underlying_shares":1322},"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2208480,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":3794,"price":32.36,"value":122773.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares represent RSU that vest on June 7, 2023, subject to continued service through the vesting date."}],"balance_after":8878,"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2208479,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":4171,"price":32.36,"value":134973.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares represent RSU that vest in three equal yearly installments, subject to continued service through each vesting date."}],"balance_after":5084,"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2208478,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2022-07-12T16:26:23.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":913,"price":32.36,"value":29544.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units (RSU), which vest on June 7, 2023, subject to continued service through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These RSU were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $29,545.00."}],"balance_after":913,"source":{"system":"sec-edgar","filing":"0001209191-22-041903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358762/000120919122041903/doc4.xml","form_type":"4"}},{"id":2406498,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":27983,"kind":"person","name":"Ryder Steven","position":1,"cik":"0001872868","reported_name":"Ryder Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (Right to Buy)","published_at":"2022-02-10T00:37:16.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 7, 2026."}],"balance_after":62000,"derivative":{"exercise_price":15.04,"expiration_date":"2032-02-07","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0000899243-22-005518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322005518/doc4.xml","form_type":"4"}}]}